Supplementary Materials

The PDF file includes:

  • Fig. S1. Genotype-Tissue Expression (GTEx) expression of DLL3 in adult tissues.
  • Fig. S2. Evaluation of DLL3-positive cells per tumor.
  • Fig. S3. DLL3 expression in patient with prostate cancer cohort by RNA-seq.
  • Fig. S4. DLL3 expression in prostate cancer cohort evaluated by NanoString.
  • Fig. S5. DLL3-positive tumors evaluated by IHC, RNA-seq, and NanoString.
  • Fig. S6. Representative images of DLL3 expression.
  • Fig. S7. DLL3 promoter methylation.
  • Fig. S8. ASCL1 expression evaluated by RNA-seq.
  • Fig. S9. Differentially expression analysis of Notch signaling genes.
  • Fig. S10. Silencing DLL3 in the NCI-H660 cell line.
  • Fig. S11. Correlation between DLL3-positive and DLL3-negative cells in a tumor biopsy.
  • Fig. S12. DLL3 expression cutoff in CTCs.
  • Fig. S13. CK expression in DLL3-positive and DLL3-negative CTCs.
  • Fig. S14. Correlation between DLL3-positive and DLL3-negative cells in CTCs.
  • Fig. S15. Expression of Notch receptors across subtypes of prostate cancer and correlation with DLL3 expression.
  • Fig. S16. In vitro toxicity of SC16LD6.5 in NCI-H660 and DU145.
  • Table S1. Clinical and pathological features of patients with CRPC-Adeno and PCA-expressing DLL3 by IHC.
  • Table S2. Genomic features of WCM1388 patient metastatic sites.
  • Table S3. Clinical features of patients with CRPC-Adeno with DLL3-positive CTCs.
  • Table S4. Serum pharmacokinetics parameters after peritoneal administration of rovalpituzumab tesirine (SC16LD6.5).

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Data file S1 (Microsoft Excel format). Tumor measurements for in vivo studies.